RecruitingNot ApplicableNCT05209568
Immune Responses to Gluten
Changes in Serum IL-2 Levels Following a Single Oral Dose of Gluten
Sponsor
Boston Children's Hospital
Enrollment
400 participants
Start Date
Jan 15, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
This is a study of immune responses after eating gluten powder in people with celiac disease and healthy controls.
Eligibility
Min Age: 2 YearsMax Age: 101 Years
Inclusion Criteria3
- On a gluten-free diet for ≥ 4 weeks
- Willing to consume gluten for research
- For the celiac disease arm, diagnosis confirmed by serology and/or histology
Exclusion Criteria6
- Pregnancy
- Wheat allergy
- Type 1 diabetes
- BMI z-score < -2
- History of more than minimal symptoms following gluten exposure on a gluten-free diet
- Comorbid condition that in the opinion of the investigator would interfere with study participation or would confound study results
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DIETARY_SUPPLEMENTGluten Powder
Single oral dose of gluten powder
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05209568
Related Trials
Tissue Destruction and Healing in Celiac Disease
NCT056800123 locations
Colonoscopy vs Stool Testing for Older Adults With Colon Polyps
NCT0561234722 locations
Efficacy of Oral Sucrosomial Iron Supplementation in Children With Celiac Disease and Iron Deficiency or Anemia
NCT075635821 location
First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
NCT0548923731 locations
Liver Steatosis in Pediatric CD Patients
NCT062066162 locations